Navigation Links
t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
Date:11/25/2008

FRANKFURT, Germany, November 25 /PRNewswire/ -- t2cure, a biopharmaceutical company developing regenerative medicine therapeutics from a patient's own stem cells, today announced that it has acquired a family of patents and patent applications from Innovectis, the technology transfer arm of Frankfurt University.

The patents cover a technology that allows for the rapid characterization of the potency of bone marrow-derived cells in the treatment of cardiovascular diseases. The potency of stem cells characterizes their potential to induce or perform repair processes in adult tissue. Recent drafts and guidelines from EMEA and FDA have made clear that potency testing will be a key criterion for batch release, and thus for market approval, of stem cell-based therapies.

"This acquisition of patent rights is a significant contribution to our regulatory strategy, as our lead product is advancing into a pivotal Phase III study in acute myocardial infarction," said Manfred Ruediger, CEO t2cure. "These patent rights complement our existing IP portfolio, supporting our commitment to make stem cell-based therapeutics a clinical reality for patients suffering from an acute heart attack or chronic heart failure."

Each year, 40,000 patients are hit by a severe heart attack in Germany alone and many more are suffering from chronic heart disease. Currently there is no treatment available that can reverse the damage to diseased heart muscle. In clinical trials, stem cell-based therapies under development by t2cure have demonstrated the potential to repair damaged tissue.

t2cure will use its technology for potency testing to confirm product specifications in the course of its upcoming pivotal Phase III study in acute myocardial infarction. This study, which will enroll up to 1,400 patients, is scheduled to enroll its first patients in the second quarter of 2009.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and is now prepared to enter Phase III. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.

    Contact

    Manfred Ruediger, CEO
    t2cure GmbH
    Bettinastrasse 35-37
    D-60325 Frankfurt am Main
    Tel: +49-69-75-61-46-87-0
    Fax: +49-69-75-61-46-87-9
    Email: info@t2cure.com
   http://www.t2cure.com


'/>"/>
SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
3. Vyta Corp Acquires 100% Ownership of BIOAGRA, LLC
4. Affitech Acquires Pharmexas Diabody Technology
5. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
6. CPA Acquires Renowned German Patent Research Specialist, SVPG
7. Circassia Acquires North American and Japanese Rights to Dopexamine
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
10. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
11. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/16/2017)... (PRWEB) , ... July 16, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Rocking ... five rocking and waving shaker models (both analog and digital) for laboratory applications ...
(Date:7/14/2017)... ... July 14, 2017 , ... Sonic ... Sonic Manufacturing Technologies has installed a solar system on its roof top. “We ... the President of Sonic, Kenneth Raab stated. The company’s proud history of social ...
(Date:7/14/2017)... ... July 14, 2017 , ... ... preparation of proteins to clean peptides for mass spectrometry (MS) analysis combining the ... The PreOmics iST Kit is based on proprietary technology that contains optimized buffer ...
(Date:7/13/2017)... ... July 13, 2017 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... the completion of a major transaction with Eurazeo PME. The reputable French private ... alliance fuels In’Tech Medical’s service offerings while leveraging the company’s manufacturing expertise and ...
Breaking Biology Technology:
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
Breaking Biology News(10 mins):